StockNews.com Downgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Thursday.

A number of other analysts also recently commented on PBH. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $78.58 on Thursday. Prestige Consumer Healthcare has a 12-month low of $58.22 and a 12-month high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 2.08 and a beta of 0.51. The business has a 50 day simple moving average of $80.52 and a 200 day simple moving average of $74.49.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the prior year, the business posted $1.07 earnings per share. The company’s revenue for the quarter was down .9% compared to the same quarter last year. On average, equities research analysts anticipate that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in the company. Quest Partners LLC grew its position in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares during the period. nVerses Capital LLC grew its holdings in shares of Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after buying an additional 400 shares in the last quarter. Huntington National Bank raised its position in Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the period. Finally, International Assets Investment Management LLC raised its position in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.